WP
OLMA icon

Woodline Partners’s Olema Pharmaceuticals OLMA Stock Holding History

Woodline Partners’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.4M Sell
751,030
-731,000
-49% -$9.79M 0.03% 549
2026
Q1 		$22.1M Buy
1,482,030
+100
+0% +$2.23K 0.08% 317
2025
Q4 		$37M Sell
1,481,930
-735,963
-33% -$13.1M 0.14% 183
2025
Q3 		$21.7M Sell
2,217,893
-1,288,000
-37% -$7.73M 0.1% 264
2025
Q2 		$14.9M Buy
3,505,893
+2,027,986
+137% +$9.04M 0.08% 349
2025
Q1 		$5.56M Buy
1,477,907
+120,428
+9% +$606K 0.04% 481
2024
Q4 		$7.91M Buy
1,357,479
+3,293
+0.2% +$32.9K 0.05% 397
2024
Q3 		$16.2M Buy
1,354,186
+501,632
+59% +$6.41M 0.14% 216
2024
Q2 		$9.22M Buy
852,554
+102,275
+14% +$1.11M 0.09% 258
2024
Q1 		$8.49M Hold
750,279
– – 0.08% 294
2023
Q4 		$10.5M Buy
750,279
+32,947
+5% +$443K 0.11% 224
2023
Q3 		$8.86M Buy
717,332
+129,280
+22% +$1.32M 0.1% 238
2023
Q2 		$5.31M Buy
+588,052
New +$3.55M 0.06% 279

Other funds holding OLMA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Woodline Partners's OLMA Position: Q2 2026 in Review

Woodline Partners reduced its Olema Pharmaceuticals (OLMA) stake by 49% in Q2 2026, selling an estimated $9.79M and leaving 751,030 shares worth $9.4M. The position accounts for 0.03% of the portfolio, ranked #549.

Woodline Partners first reported a position in OLMA in Q2 2023 and has held it in 13 quarters since. The position peaked at $37M in Q4 2025. 185 funds tracked by Wall St. Rank hold OLMA as of Q2 2026.

  • Woodline Partners held 751,030 shares of Olema Pharmaceuticals worth $9.4M as of Q2 2026.
  • Woodline Partners sold 731,000 Olema Pharmaceuticals shares in Q2 2026, an estimated $9.79M.
  • Olema Pharmaceuticals made up 0.03% of Woodline Partners's portfolio in Q2 2026, its #549 holding.
  • Woodline Partners first reported a position in Olema Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Woodline Partners's Olema Pharmaceuticals position peaked at $37M in Q4 2025.
  • 185 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q2 2026.

Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.